Mark W McDonald

10PUBLICATIONS
66CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 12, 2025
Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer.

Nicole C Schmitt, William A Stokes, James E Bates

|Apr 14, 2025
Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163.

Nabil F Saba, Yael Flamand, Derrick T Lin

|Aug 21, 2024
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.

Nabil F Saba, Ritu Chaudhary, Kedar Kirtane

|Jul 02, 2024
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.

Nabil F Saba, Conor E Steuer, Asari Ekpenyong

|May 02, 2024
Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage.

Saagar Pamulapati, Marin Abousaud, Yixuan Li

|Apr 03, 2023
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.

Nabil F Saba, Conor E Steuer, Asari Ekpenyong

Pageof 2

Frequent Collaborators

9 joint publications

Nabil F Saba

6 joint publications

Dong M Shin

5 joint publications

Nicole C Schmitt

5 joint publications

William Stokes